Cytomedix is to downsize its R&D activities in a renewed focus on profitability, in what is its second reorganization in as many months.
Cytomedix is to downsize its R&D activities in a renewed focus on profitability, in what is its second reorganization in as many months.
As part of its latest initiative, the company's will "substantially conclude" support for the RECOVER-Stroke trial of its adult stem...
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
